当レポートでは、3種の主要ドラッグデリバリー（薬物送達）技術部門の主要動向について調査分析し、各種ドラッグデリバリー技術の概要、主要アプリケーションエリア、現在利用可能な製品の概要と製品開発動向、主要製品の売上予測（〜2020年）、主なスペシャリストディベロッパーの分析などをまとめ、概略下記の構成でお届けいたします。
Abstract
|
|
- examination of trends and advances in the three major drug delivery sectors
- Unique sales forecasts to 2020 for key products
- Critical analyses of 58 specialist developers driving the drug delivery
market onwards
|
Increasingly, pharmaceutical companies are turning to drug delivery developers
to overcome a range of challenges in getting novel new medicines and
formulations effectively and safely delivered. Indeed, it can be argued that
identifying an efficient delivery method is as important as the therapy
itself. This new report assesses three key emerging sectors in the drug
delivery field that will play a crucial role in tackling a range of delivery
issues associated with these new classes of drugs in key therapeutic areas
such as cancer, CNS, cardiology, respiratory and ophthalmology.
This report provides a detailed insight into the current and future market and...
- Provides an overview of the marketplace, outlining current thinking on the
technologies being researched and employed
- Identifies key application areas
- Appraises currently available products which utilise advanced delivery
platforms
- Examines new product developments from major specialist drug delivery
companies, critically analysing their prospects
- Allows ready comparison on different technologies within a company' s
portfolio.
Use this report to...
- Assess the strengths and weaknesses of competing products/technologies in
the context of specific delivery sectors and development companies
- Identify and review licensing and collaborative partners
- Understand the merits and applications of the main approaches being
researched.
‘...A complete analysis packed with market facts, sector forecasts to 2020 and detailed company evaluations...’
Lipid-based delivery
Many new chemical entities are poorly water soluble which may affect a drug' s
bioavailability and efficacy. Advanced drug delivery systems using
biocompatible lipid-based technologies can be used to improve solubility,
increase bioavailability (enhance absorption) and efficacy, helping to reduce
the level of drug dosage and decrease the incidence and severity of adverse
effects.
To date more than a dozen products have been approved that utilise some of the
first generation lipid-based technologies, pioneered by Elan Pharmaceuticals,
Enzon, Gilead Pharmaceuticals, ALZA (acquired by Johnson & Johnson), Skye
Pharma, and The Liposome Company (acquired by Elan Pharmaceuticals). These
products encompass anaesthetics, antiinfectives and oncology agents and
together generate over US$1.85 billion in sales annually.
Research activity is intensive and the top 20 drug delivery specialists are
currently investigating more than 75 products in preclinical and clinical
development; over half of these products (c.46 products) are likely to reach
the market by 2020 to generate global sales in excess of US$2.6 billion by
2020.
Questions answered
- What are the competing technologies to Lipocine' s Lip' ral?
- Which products in research exploit Aradigm' s proprietary inhalable drug
technology?
- Who is bank-rolling NanoBio' s R&D programme?
- Tekmira has 6 potential product launches coming up - what are the sales
forecasts to 2020?
- What research is being undertaken with lipid-based platforms for the
delivery of targeted products?
Polymer-based delivery
The pharmaceutical industry has been utilising advanced polymer-based delivery
technologies to improve the pharmacokinetics and targeted delivery of small
and large molecule drugs.
To date more than two dozen products have been approved that utilise
PEGylation technologies developed by some of the industry pioneers, such as
ALZA, Endo Pharmaceuticals and Nektar Therapeutics. In addition, several
specialists have developed controlled-release polymer matrix to prolong the
release of active pharmaceutical ingredients in situ with technologies
developed by Debiopharm Group and Durect.
By 2020 we forecast that nearly 60 novel polymer-based products could reach
the market to generate global sales in excess of US$5 billion through improved
pharmacokinetics of approved and new compounds, as well as the emergence of
novel biologics, nucleic acidbased medicines and small molecule agents.
Questions answered
- Which companies are working in the colonic drug delivery area?
- Which company acquired Biocompatibles International to gain access to the
polymer-based bead technology sector?
- How important will the urological treatment Urocidin be to Endo
Pharmaceutical' s financial health?
- What opportunities are there in polymer-based transdermal delivery?
Biovectors/Gene Therapy/Vaccines
During the last twenty years there have been significant advances in the
manufacture, development and delivery of gene therapies, RNA therapies and
vaccines. No single biovector stands out for each field and many different
development strategies have been adopted to optimise delivery.
Gene-related medicines have achieved limited success to date - no gene
therapies have been approved and only a few antisense drugs have carved out a
therapeutic niche in ocular diseases (Vitravene; CMV, Macugen; wet AMD).
However, R&D investment for gene related products continues to grow at a fast
rate and this highlights the challenges and opportunities which face
developers, delivery technologists and regulators in this field.
In contrast, interest in the vaccine market has rocketed fuelled by biodefence
programmes and the outbreak of avian influenza as well as advances in vaccine
production technologies which has lowered the barrier to entry for the smaller
players. Whilst infectious diseases, particularly influenza and HIV, remain a
major area of interest, therapeutic vaccines are emerging to gain a share of
the marketplace.
Questions answered
- Which product sector is set to exceed sales of US$2 billion by 2020?
- Which company commenced Phase II trials in January 2011 for a DNA vaccine
to treat leukaemia?
- Which company has AtuRNAi products in Phase II development for Macular
Oedema and Agerelated Macular Degeneration?
- 10 companies are active in the field of oncology. Who are they and what is
their pipeline?
Figure 1:
Impact of aqueous solubility and membrane permeability of choice of advanced delivery system
Source: modified from David J Hauss, Bristol-Myers Squibb' s presentation
entitled “Lipid-based systems for oral drug delivery.”
Table of Contents
Volume 1 - Lipid-based delivery technologies
ABOUT THE AUTHOR
EXECUTIVE SUMMARY
INTRODUCTION
- Types of lipid-based delivery platforms
APPLICATIONS IN DRUG DISCOVERY AND PRODUCT DEVELOPMENT
- Oral & buccal
- Parenteral
- Pulmonary/Intranasal
- Transdermal/Topical
DELIVERY PROFILES
- Nano-enabled delivery
- Controlled delivery
- Targeted delivery
APPLICATIONS IN DIFFERENT THERAPEUTIC AREAS
- Oncology
- Infectious diseases
- CNS & Pain
- Respiratory
- Cardiology
- Ocular
- Other
TOP 20 COMPANY PROFILES
- AlphaRx Corporation
- Aphios Corporation
- Aradigm Corporation
- Axentis Pharma AG
- Azaya Therapeutics
- Bio-Path Holdings
- Camurus AB
- Celsion Corporation
- Clavis Pharma ASA
- Cornerstone Pharmaceuticals
- Insys Therapeutics
- Latitude Pharmaceuticals
- Lipocine
- Marina Biotech
- Merrimack Pharmaceuticals
- NanoBio Corporation
- Novagali Pharma SA
- Talon Therapeutics
- Taiwan Liposome Company
- Tekmira Pharmaceuticals Corporation
UP & COMING LIPID-BAS ED DRUG DELIVERY SPECIALISTS
CONCLUSIONS
BIBLIOGRAPHY & ENDNOTES
Volume 2 - Polymer-based delivery technologies
EXECUTIVE SUMMARY
INTRODUCTION
TYPES OF POLYMER-BAS ED DELIVERY PLATFORMS
APPLICATIONS IN DRUG DISCOVERY AND PRODUCT DEVELOPMENT
- Oral & buccal
- Parenteral
- Transdermal
DELIVERY TRENDS
- Nano-enabled delivery
- Controlled delivery
- Targeted delivery
THERAPEUTIC TRENDS
- Oncology
- Neurology & Pain
- Cardiology
- Gastroenterology
- Metabolic
- Other
TOP 20 COMPANY PROFILES
- Access Pharmaceuticals
- Alkermes
- BioDelivery Sciences International
- BTG International
- Calando Pharmaceuticals
- Debiopharm Group
- Durect Corporation
- Expression Genetics
ENDO PHARMACEUTICALS
- Enzon Pharmaceuticals
- Labopharm
- Mersana Therapeutics
- Mountain View Pharmaceuticals
- Nanocarrier
- Nektar Therapeutics
- OctoPlus N.V
- Samyang Pharmaceuticals
- Supratek Pharma
- SurModics
- Teikoku Pharma USA
UP & COMING POLYMER-BASED DRUG DELIVERY SPECIALISTS
OUTLOOK
BIBLIOGRAPHY & ENDNOTES
Volume 3 - Biovectors: Gene Therapies/RNA Therapeutics/Vaccines
EXECUTIVE SUMMARY
INTRODUCTION
TYPES OF BIOVECTORS
- Viral vectors
- Adeno-associated virus vectors
- Adenovirus vectors
- Alphavirus vectors
- Lentivirus vectors
- Poxvirus vectors
- Other viral vectors
- Non-viral vectors
- Bacteria
- Yeast
- Advanced drug delivery systems
- Lipid-based delivery
- Polymeric-based delivery
- Delivery devices
APPLICATIONS IN THE DEVELOPMENT OF GENE THERAPIES, RNAI THERAPEUTICS AND VACCINES
DELIVERY TRENDS
- Gene Therapies
- RNA Therapeutics
- Vaccines
THERAPEUTIC TRENDS
- Gene Therapies
- RNA Therapeutics
- Vaccines
TOP 20 COMPANY PROFILES
- Gene Therapies
- RNA Therapeutics
- Vaccines
GENE THERAPY DELIVERY
- Ark Therapeutics
- Ceregene
- Expression Genetics
- Neurologix
- Oxford BioMedica
RNA THERAPEUTIC DELIVERY SPECIALISTS
- Alnylam Pharmaceuticals
- Calando Pharmaceuticals
- CureVac GmbH
- Marina Biotech
- Santaris Pharma A/S
- Silence Therapeutics
- Tekmira Pharmaceutical Corporation
VACCINE DELIVERY SPECIALISTS
- Crucell N.V.
- GlobeImmune
- Inovio Pharmaceuticals
- Ichor Medical Systems
- Juvaris BioTherapeutics
- Lipotek Pty
- Vical
- VIRxSys
UP & COMING GENE THERAPY, RNAI THERAPEUTICS AND VACCINE DELIVERY SPECIALISTS
OUTLOOK
BIBLIOGRAPHY & ENDNOTES
